Partnerships

Why Partner with BioTissue

  • Pioneer in amniotic tissue space​
  • Proven scientific data to support multiple platforms
  • Robust clinical pipeline with multiple assets in late-stage FDA/BLA approval process​
  • Regulatory approvals, clinical data, and capital required create significant barriers to entry for competitors to enter amniotic tissue marketplace
  • Strong Financial Profile​ with institutional investors (EW, Ballast Point)

BioTissue is the leader in innovative technologies using products derived from human amniotic membrane tissues. Since its inception in 1997, the Company has pioneered the clinical application of human placental tissues – more than 790,000 patients have been treated with BioTissue products and the Company’s groundbreaking scientific and clinical achievements have been documented in more than 390 peer-reviewed publications.

37​Y

National Institutes of Health (NIH) Funding​

790,000+​

Human Clinical Applications​

390+​

Peer-Reviewed Publications​

1st

to establish Level 1 CPT Codes for Amniotic Membrane Transplantation

100+

Clinical Training Opportunities Each Year

6 INDs

Three in Phase 2 & 3 Clinical Trials for BLA Approval

Our Focus

Unmet Patient Needs

We are focused on giving healthcare providers cost-effective solutions to successfully address previously unmet patient needs: 

Ophthalmic and optometric indications

It is estimated that the total economic burden of eye disorders and vision loss in the U.S. is $139 billion.1

Advanced wounds

A conservative estimate of the cost of caring for these wounds exceeds $50 billion per year in the U.S.2-5

Musculoskeletal applications

In 2011, the total indirect and direct costs for musculoskeletal disorders was estimated to be $874 billion, or 5.7 % of U.S. Gross Domestic Product.6

Non-opioid alternative to managing pain

The total economic burden of prescription opioid misuse in the U.S. is $78.5 billion annually with an estimated 128 people dying each day after overdosing on opioids.7

The Right Healing. The Right Product.

Prokera® Classic

Maintains orbital space with a symblephoron ring for cases where prevention of closure or adhesion is a concern.

Prokera Slim

Uses ComfortRing™ technology for a lower profile device that contours to the ocular surface to maintain comfort in treatment.

Prokera Plus

Maximizes the therapeutic benefit with a double layer of cryopreserved amniotic membrane tissue, for patients who need intensive treatment.

Prokera Clear

Provides patient with visual acuity during treatment with a 6mm ClearView™ aperture, which is crucial in monocular needs.

Rapid Recovery. Lasting Benefit.

AmnioGraft®, a cryopreserved amniotic membrane graft, supports accelerated post-op recovery and ensures superior patient outcomes when used in ocular surface reconstructive procedures.8-11

AmnioGuard® is an ultra-thick, cryopreserved amniotic membrane graft that suppresses inflammation, promotes healing, and provides durable tensile strength to avoid surgical challenges associated with reconstructive procedures.12-15

What Makes Our Ocular Products Different?

Offer your patients better healing with Prokera, the ONLY amniotic membrane medical device…

Recognized by FDA for:

  • Wound Healing
  • Reducing inflammation
  • Minimizing corneal scarring16
  • Inhibiting angiogenesis

Proven to be equivalent to fresh tissue17

  • Mantains the biologic and structural integrity of the tissue.18
  • Contains HC-HA/PTX3, a key protein found in fresh tissue.19

Meeting the highest quality standards20

  • An AATB accredited tissue bank
  • The only ISO certified manufacturer of amniotic membrane products
  • Over 300,000 successful transplants

Demonstrating 20 years of proven clinical performance

  • More than 350 peer-reviewed publications to date
  • Associated with corneal nerve regeneration, which play a key role in tear film stability and ocular surface health21
  • May accelerate healing of the ocular surface, with sustained reduction of signs and symptoms of dry eye22

Strong Health Economic Value

01
Prokera placement is one of the most profitable procedures for Ophthalmologists/Optometrists
02
Cataract w/ OSO optimization allows for practices to utilize ASCRS protocol to grow revenue
Current

Physician Education & Training

We provide educational support through the following programs:

  • BioTissue 360 Visit Programs
  • Ocular Surface Biologics Course (OSBC)
  • Leadership Training Summits
  • Pro Ed Webinar Series
  • DocMatter Peer-to-Peer Online Resource
  • Physician Portal One-Stop Clinical Resource
  • Local Peer-to-Peer

Practice Growth Support

  • Provide superior outcomes for happier & loyal patients
  • Establishment of Level 1 CPT Codes
  • Favorable practice & patient economics compared to other standards of care
  • Reimbursement and coding support
  • Continued payer engagement
  • Industry support via AAO (both), AOA, ASCRS, & Others
  • Full consultative support from your rep and HQ team
  • Trackable Med (direct to to patient advertising)

Marketing Tool Kit

The BioTissue Physician Marketing Toolkit provides physicians and their staff with simple tools for promoting our products on your print and digital marketing channels.

References
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664309/
Kuhn BA, Coulter SJ. Balancing ulcer cost and quality equation. Nurs Econ. 1992;10(5):353–359.
Hess CT. Putting the squeeze on venous ulcers. Nursing. 2004;34(Suppl Travel):8–13.
Driver VR, Fabbi M, Lavery LA, Gibbons G. The costs of diabetic foot: the economic case for the limb salvage team. J Am Podiatr Med Assoc. 2010;100(5):335–341.
Gordon MD, Gottschlich MM, Helvig EI, Marvin JA, Richard RL. Review of evidence-based practice for the prevention of pressure sores in burn patients. J Burn Care Rehabil. 2004;25(5):388–410
https://www.sciencedaily.com/releases/2016/03/160301114116.htm
https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis
Solomon A, Pires RTF and Tseng SCG. Amniotic membrane transplantation after extensive removal of primary and recurrent pterygia. Ophthalmology. 2001; 108: 449-60.
Kheirkhah A, Casas V, Esquenazi S, et al. New surgical approach for superior conjunctivochalasis. Cornea. 2007;26(6):685-691.
Kheirkhah A, Casas V, Blanco G, Li W, Hayashida Y, Chen YT, Tseng SC. Amniotic membrane transplantation with fibrin glue for conjunctivochalasis. Am J Ophthalmol. 2007;144(2):311-3.
Georgiadis NS, Terzidou CD. Epiphora caused by conjunctivochalasis: treatment with transplantation of preserved human amniotic membrane. Cornea. 2001; 20(6):619-621.
Sheha H, Tello C, Al-Aswad L, Sayed M, Lee R. Outcomes of the Shunt Tube Exposure Prevention Study (STEPS), a randomized clinical trial. Opthalmol Glaucoma. [Online] August 16, 2019.
Finger PT, Jain P, Mukkamala SK. Super-thick amniotic membrane for ocular surface reconstruction. Am J Opthalmol. 2019;198:45-53.
Slentz, D. and Nelson, C. (2019). Novel Use of Cryopreserved Ultra-thick Human Amniotic Membrane for Management of Anophthalmic Socket Contracture. Ophthalmic Plastic and Reconstructive Surgery, 35(2), pp.193-196.
Johnson, Amy, et al. “Understanding the impact of preservation methods on the integrity and functionality of placental allografts.” Annals of plastic surgery 79.2 (2017): 203-213.
Morkin, Melina and Hamrah, Pedram. “Ecacy of self-retaining cryopreserved amniotic membrane for treatment of neuropathic corneal pain” The Ocular Surface. 9 October 2017.
an, EkKia, and Marissa Cooke. “Structural and Biological Comparison of Cryopreserved and Fresh Amniotic Membrane Tissues.” J. Biomaterial Tissue Engineering, vol. 4, no. 5, ser. 2014, pp. 379–388. 2014.
John, Daniel, and Randall Spencer. Placental Tissue Grafts and Improved Methods of Preparing and Using the Same. 17 Oct. 2017.
Cooke, M., and E.K. Tan. “Comparison of Cryopreserved Amniotic Membrane and Umbilical Cord Tissue with Dehydrated Amniotic Membrane/Chorion Tissue.” Journal of Wound Care, vol. 23, no. 10, ser. 2014. 2014.
Unger, Steven. “Request for Designation.” Received by David J. Bloch, 28 Nov. 2001.
John, Thomas. “Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease.” Journal of Ophthalmology, vol. 2017, doi:10.155/2017/6404918.
McDonald et al. “Treatment Outcomes in the Dry Eye Amniotic Membrane (DREAM) Study.” Presented at AAO Annual Meeting 2017, PO055